MX2018006986A - Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. - Google Patents

Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Info

Publication number
MX2018006986A
MX2018006986A MX2018006986A MX2018006986A MX2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A MX 2018006986 A MX2018006986 A MX 2018006986A
Authority
MX
Mexico
Prior art keywords
natriuretic peptide
type natriuretic
peptide variants
treat osteoarthritis
osteoarthritis
Prior art date
Application number
MX2018006986A
Other languages
English (en)
Spanish (es)
Inventor
K Pinkstaff Jason
A O'neill Charles
M Oppeneer Todd
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2018006986A publication Critical patent/MX2018006986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018006986A 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis. MX2018006986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
MX2018006986A true MX2018006986A (es) 2018-09-05

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006986A MX2018006986A (es) 2015-12-08 2016-12-08 Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.

Country Status (17)

Country Link
US (2) US11202819B2 (https=)
EP (2) EP4019038A3 (https=)
JP (1) JP7104625B2 (https=)
KR (1) KR102941538B1 (https=)
CN (1) CN108697766A (https=)
AU (2) AU2016365751B2 (https=)
CA (1) CA3007315A1 (https=)
DK (1) DK3386531T3 (https=)
ES (1) ES2901769T3 (https=)
HR (1) HRP20211908T1 (https=)
HU (1) HUE057083T2 (https=)
IL (1) IL259690B2 (https=)
MX (1) MX2018006986A (https=)
PL (1) PL3386531T3 (https=)
PT (1) PT3386531T (https=)
RU (1) RU2759679C2 (https=)
WO (1) WO2017100400A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
IL297375B2 (en) 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low NPR–C binding
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
AU2019260810A1 (en) * 2018-04-27 2020-11-19 Remy Biosciences, Inc. New medical devices, delivery vehicles and manufacturing thereof
EP3923906A1 (en) * 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
US20240238428A1 (en) * 2021-05-11 2024-07-18 Texas Tech University System Targeted selenium conjugates as countermeasures for viral and cellular pathogens
AU2022407450A1 (en) * 2021-12-07 2024-07-11 Biomarin Pharmaceutical Inc. CNP Therapy
EP4612167A1 (en) 2022-11-02 2025-09-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CN1960757A (zh) * 2004-03-31 2007-05-09 中尾一和 身高增加用组合物
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
ES2608457T3 (es) * 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Also Published As

Publication number Publication date
JP7104625B2 (ja) 2022-07-21
IL259690A (en) 2018-07-31
HUE057083T2 (hu) 2022-04-28
WO2017100400A2 (en) 2017-06-15
EP3386531B1 (en) 2021-10-13
US12214015B2 (en) 2025-02-04
IL259690B (en) 2022-10-01
CA3007315A1 (en) 2017-06-15
WO2017100400A3 (en) 2017-10-26
RU2759679C2 (ru) 2021-11-16
AU2016365751B2 (en) 2023-12-21
US11202819B2 (en) 2021-12-21
EP3386531A2 (en) 2018-10-17
AU2016365751A1 (en) 2018-06-21
RU2021132347A (ru) 2022-03-24
KR20180088459A (ko) 2018-08-03
RU2018124600A3 (https=) 2020-01-13
KR102941538B1 (ko) 2026-03-19
JP2019505486A (ja) 2019-02-28
PL3386531T3 (pl) 2022-02-28
HRP20211908T1 (hr) 2022-03-04
DK3386531T3 (da) 2022-01-03
PT3386531T (pt) 2021-12-29
CN108697766A (zh) 2018-10-23
ES2901769T3 (es) 2022-03-23
US20190247467A1 (en) 2019-08-15
EP4019038A2 (en) 2022-06-29
US20220160836A1 (en) 2022-05-26
EP4019038A3 (en) 2022-09-28
AU2024201852A1 (en) 2024-04-11
IL259690B2 (en) 2023-02-01
RU2018124600A (ru) 2020-01-13

Similar Documents

Publication Publication Date Title
MX2018006986A (es) Uso de variantes del peptido natriuretico tipo c para tratar osteoartritis.
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
NI201700042A (es) Composiciones y métodos de uso para tratar trastornos metabólicos.
BR112018001761A2 (pt) uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
ZA201803366B (en) Antibody molecules to april and uses thereof
MX2022003184A (es) Variantes del cnp y sus conjugados.
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2016012880A (es) Cadena j modificada.
BR112016024494A8 (pt) análogo de peptídeo e seu uso
BR112022011902A2 (pt) Terapias de combinação
ECSP17003946A (es) Anticuerpos antagonistas del interferón alfa y omega
UY37589A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
UY37590A (es) COMPUESTOS MODULADORES DEL RECEPTOR DE HIDROCARBUROS ARÍLICOS (AhR)
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
EA202191471A1 (ru) Противовоспалительные полипептиды
MX2020006355A (es) Pirrolidinamidas ii sustituidas.
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
PH12017500426A1 (en) Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
ECSP15014925A (es) Compuestos para tratar el bloqueo de remielinizacion en enfermedades asociadas con la expresion de la proteina de envoltura herv-w
MX375653B (es) Valvula pretensada para un dispositivo funcional medico y un dispositivo funcional medico.
MX2017014128A (es) 2-tiopirimidinonas.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX393695B (es) Metodos para tratar trastornos de hiperpigmentacion.